Biocracked
**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
Research

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

Dr. Synapse · · 5 min read

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

Da'awar da ake yi game da CBL‑514 ba ita ce “yana narkewa” kitse ba. Da'awar ita ce tana tilastawa ƙwayoyin kitse su shiga mutuwar ƙwaya (apoptosis) a wuri da aka saka maganin. Wannan bambanci ne ke ƙayyade duk abin da ake tsammani za a gani, abin da masu bincike suka auna, da abin da hujja ke nuna (ko ba ta nuna ba).

Lura kan suna: Sinadarin CBL‑514, ba “CL‑514” ba. Wannan shi ne ƙwanƙwasa ƙwayar da kamfanin Caliway Biopharmaceuticals (New Taipei City, Taiwan) ke gwadawa. Ba ƙaraɗi ba ne, ba maganin shan ruwa ba, kuma ba samfurin da aka amince da shi ga jama'a ba. A cikin gwajin da ake magana a kai an bayar da shi a matsayin allurar subcutaneous a cikin ƙashin kitse.

Da'awar kwayoyin: DYRK1b, caspase‑3, da Bax/Bcl‑2

Takardar Phase 2 ta 2025 ta bayyana CBL‑514 a matsayin "ƙananan allurar da ke haifar da lipolysis kuma ke ƙarfafa apoptosis na adipocyte don rage kitse a ƙasa da fata a gwaje‑gwajen marasa cuta." Hanyar aiki da aka fi bayani ta fito ne daga takardar Phase 2a (Goodman et al., 2022) wadda ta ce gwaje‑gwajen marasa cuta sun nuna CBL‑514:

  • yana hanawa DYRK1b, wani kinase da ke kula da tsawon rayuwar sel;
  • yana ƙara yawan caspase‑3 da Bax/Bcl‑2, waɗanda ke jagorantar apoptosis;
  • yana haifar da apoptosis na adipocyte, a in‑vitro da in‑vivo.

Takardar Phase 2a ta kuma ba da rahoton lipolysis a in‑vitro da rage kitse a ƙasa da fata a gwaje‑gwajen dabbobi.

A takaice, da'awar ita ce maganin na katsalandan da siginar tsira a ƙwayoyin kitse kuma yana tilastawa sel ɗin shiga cikin hanyar mutuwarsu. Caspase‑3 shi ne enzyme mafi muhimmanci wajen kaddamar da apoptosis. Daidaiton Bax/Bcl‑2 kuma alama ce da ake amfani da ita don tantance ko sel na karkata ga mutuwa ko tsira.

Abubuwan da ba mu sani ba

Akwai manyan ƙuntatawa. Sakamakon da aka ambata su ne a rahotannin sirri da ba a wallafa ba daga Caliway, don haka kamfanin ne ya bayar da su ba tare da cikakken bayani a cikin takardar Phase 2 ba. Haka kuma, takardun da aka buga ba su bayyana tsarin sinadarin CBL‑514 ba. Ba tare da wannan bayani ba, ba wanda zai iya tantance menene ainihin sinadirin, yadda yake ɗaure DYRK1b, ko kuma ko inhibtion na DYRK1b ke da cikakkiyar hujja ba.

Mutuwar ƙwayar kitse a wuri ɗaya, ba ƙara metabolism ba

Mekanik da ake ba da shi ba yana da alaka da ƙara saurin metabolism ko ƙara yawan kuzari gaba ɗaya. Manufar ita ce a wuri: a saka maganin a cikin kitse na ƙasa da fata, a haifar da apoptosis a wannan wuri, sannan a auna raguwar kauri da girman kitse ta hanyar ultrasound.

Bayanan nauyin jiki daga gwajin Phase 2 sun dace da wannan tunani. Canjin nauyin ba ya bayyana sosai: +0.45 kg a makon 4 da +0.02 kg a makon 8 a ƙungiyar CBL‑514, yayin da placebo ya rage –0.76 kg da –0.26 kg. Masu rubutu sun ce ba su ga canjin nauyi ko BMI mai ma’ana ba, kuma sun lura da raguwar kitse a wuri ɗaya har a wasu mahalarta da suka ƙara fiye da 1 kg (ba a bayyana cikakken bayanin ba). Wannan shi ne raguwar girman kitse a wuri, ba raguwar ƙarfi ba.

Abin da gwajin ɗan adam ya auna

Binciken Phase 2 (Gold et al., Aesthetic Surgery Journal, 2025) an tsara shi a matsayin randomized, single‑blind, placebo‑controlled a cibiyoyi biyar a Amurka da Australia. Mahalarta sun karɓi allura har zuwa huɗu a tazara na makonni 4. Kowace allura ta ba da 2.4 mL na CBL‑514 a 2 mg/cm², har zuwa 600 mg a kowanne magani, ko ruwa mai gishiri a matsayin placebo. Girman kitse an ƙididdige shi daga kaurin ultrasound a maki huɗu da aka ninka da yanki na cm² 300.

Masu rubutu sun ba da rahoton cewa gwajin ya cika babban manufa. A cikin nazarin intention‑to‑treat, 63.9 % na mahalarta CBL‑514 (23/36) sun sami ragin girman kitse na aƙalla 150 mL a makon 4, yayin da 17.4 % (4/23) na placebo suka cimma haka. A makon 8 adadin su ne 69.6 % (16/23) vs 0 % (0/16). Canjin matsakaicin least‑squares daga asali a ƙungiyar CBL‑514 ya kasance ‑199.80 mL a makon 4 da ‑209.46 mL a makon 8.

Wadannan sakamako ba su da alaƙa da hujjar mekanik. Gwajin ya auna girma, kauri, hotuna, da aminci. Bai ba da biopsi na ɗan adam ko bayanan caspase ba, don haka babu wani abu a cikin takardar da ke nuna cewa an sami inhibtion na DYRK1b ko apoptosis na adipocyte a mutanen da aka yi wa magani. Bayanan ɗan adam kawai sun nuna raguwar kaurin kitse da ultrasound ke auna. Bayanin apoptosis ya kasance har yanzu tunani da aka ɗauka daga gwaje‑gwajen marasa cuta.

Karanta sakamakon da hankali

Wasu ƙuntatawa na da muhimmanci ga duk mai nazari:

  • Single‑blind kawai – Mahalarta sun kasance blinded, amma masu bincike, ma’aikatan wurin, da masu tallafa ba su kasance ba.
  • Yawan mutuwar mahalarta – Daga mahalarta 75 da aka yi wa magani, 37 (49.3 %) ba su kammala gwajin ba. Adadin wadanda suka fice ya ragu a kowanne mataki, kuma yawan mahalarta da suka bi protocol ya rage zuwa mutane 30 kacal.
  • Shiga kamfanin – Caliway ta halarci tsara gwaji, tattara bayanai, nazari, fassara, da yanke shawarar gabatarwa.
  • Samfurin gwaji na bincike – Ba a yi gyara ba don yawan gwaje‑gwaje.
  • Mahalarta mafi yawansu mata ne (94 % a ƙungiyar CBL‑514).

Masu rubutun sun ce sakamakon "ya yi daidai da na liposuction" kuma "yana bayyana fiye da wasu gwaje‑gwajen cryolipolysis". Waɗannan fassarori ne na masu rubutu; hanyoyin auna sun bambanta, kuma ba a yi kwatancen kai tsaye ba.

Yadda wannan ya bambanta da ATX‑101

Maganin da FDA ta amince da shi don rage kitse shi ne ATX‑101 (deoxycholic acid, Kybella), wanda aka amince da shi ne kawai don kitse a ƙasan goshi (submental). ATX‑101 yana aiki ta hanyar adipocytolysis – wani yanayi daban da apoptosis da aka ƙayyade don CBL‑514 – kuma takardun suna nuna damuwa game da yuwuwar rauni ga ƙwayoyin da ba a nufi ba.

CBL‑514 an bayyana shi a matsayin maganin da ke ƙarfafa rage kitse ba tare da necrosis na fata, ulceration, ko rauni na ƙashi ba a gwaje‑gwajen marasa cuta. Masu rubutu na Phase 2 sun ba da rahoton babu irin waɗannan abubuwa a gwajinsu.

Wannan yana nuna cewa sakamakon na daga matakin tsakiyar bincike ne, ba hujja ba don amincin dogon lokaci. Gwajin ya yi ƙanƙanta, ya samu yawan mutuwar mahalarta, kuma ba a tsara shi don magance tambayoyin aminci na tsawon lokaci ba.

Karshe

Mekanik da aka ƙayyade na CBL‑514 shi ne: hanawa DYRK1b, ƙara yawan caspase‑3 da Bax/Bcl‑2, da haifar da apoptosis na adipocyte a wuri da aka yi magani. Bayanan ɗan adam sun nuna raguwar kitse da aka auna ta ultrasound a kan placebo. Hanyar da ke haɗa waɗannan biyun ba a nuna a cikin mutane ba, kuma hujjar kwayoyin na fitowa ne daga rahotannin kamfani da ba a wallafa ba. CBL‑514 har yanzu yana cikin gwaji, kuma wannan labarin ba jagora bane don amfani.

Hanyoyin da aka ambata

  • Phase 2: Gold M, et al. Aesthetic Surgery Journal. 2025;45(6):611‑620. Full text (PMC12080885) | PubMed | DOI
  • Earlier Phase 2a (open‑label): Goodman GJ, et al. Aesthetic Surgery Journal. 2022;42:NP662‑NP674. PMC9384315 | DOI

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

BY DR. SYNAPSE ·

CBL‑514 wani allura ne da ake bincike don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. A gwajin mataki na 2 da aka gudanar a 2025 tare da mahalarta 76 da aka raba ta bazuwar, an samu raguwar ƙimar kitse da aka auna ta ultrasound idan aka kwatanta da saline, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Ƙididdigar ta gabatar da ƙirar gwajin, ƙimar 2 mg/cm², cikakkun bayanan tasiri da ƙananan lambobi, da hanyar DYRK1b/caspase da kamfanin ya ba da rahoto. An kuma bayyana iyakokin: ƙirar single‑blind, haɗin gwiwar mai tallafa, kusan 49 % rashin kammalawa, gajeren lokaci na bibiyar, da yawan samfurin mata.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

BY DR. SYNAPSE ·

Gwaje‑gwajen CBL‑514 su ne gwaje‑gwajen allura da ke binciken tasirin wannan magani, inda adadin 600 mg ke nufin iyakar adadin da ake amfani da shi a kowanne magani a gwaji, ba adadin da za a ci ba. Wannan makala ta bi takaitaccen binciken Phase 2a don tantance ƙimomi (1.2, 1.6, 2.0 mg/cm² a kan 150 cm², n=43, buɗe‑label) kuma ta fayyace asalin adadin 24.96 % da aka ambata. Sannan ta duba Phase 2 da aka gudanar da placebo, inda aka ci gaba da ƙimar 2.0 mg/cm² amma an ninka yanki zuwa 300 cm² tare da iyaka ta 600 mg. Za ku ga dalilin da yasa adadin mg ba za a iya kwatanta su tsakanin gwaje‑gwajen ba, abin da aka rubuta game da tsaro, da kuma dalilin da ya sanya har yanzu ba a amince da shi ba ko ba da shawara ba.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

BY HELIX WARD ·

Binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 bai nufin rage nauyin jiki ba; an duba ko alluran da aka yi a ƙirji za su iya rage aƙalla mililita 150 na kitse a ƙarƙashin fata ta hanyar ultrasound. Bayan makonni 8, kashi 69.6 % (16/23) na masu karɓar CBL‑514 sun cimma wannan ragi, yayin da babu ɗaya a rukunin placebo. Duk da haka, matsakaicin nauyin jiki bai ragu ba (ƙara 0.02 kg) kuma kusan rabi na mahalarta ba su kammala binciken ba. Martani a wurin allura ya kasance gama‑gari, ciki har da ƙura a fata a 71.4 % da zafi mai tsanani a 18.4 %. Wannan shine abin da binciken ya nuna da abin da bai nuna ba.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?

BY DR. SYNAPSE ·

CBL‑514 ta wuce gwajin mataki na biyu da aka sarrafa placebo a mujallar *Aesthetic Surgery Journal*, inda marubuta suka ce ta cika manyan manufofin da aka saita. Sai dai wannan bitar na nuna dalilan da ya sa dole a duba ƙirar gwajin sosai: an yi amfani da blind guda ɗaya, masu bincike da mai tallafa ba su da ɓoye, kuma mai tallafa ya shiga ƙirƙira, tantancewa da rubuta sakamakon. Daga cikin mahalarta 75 da aka ba da magani, kawai 38 suka kammala, kuma ƙungiyar da aka yi nazari a kai ta ƙunshi mutane 30 kacal. An dakatar da bibiyar bayan makonni 8, kuma samfurin ya fi yawa mata da fararen fata. Wannan labarin zai fayyace abin da gwajin zai iya tabbatarwa, abin da ba zai iya ba, da dalilin da ya sa ba za a ɗauke shi a matsayin shawara ta likita ko hujja da aka amince da ita ba.

This page is available in